Journal of Clinical Oncology, Vol 15, 1608-1616, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies

ZS Pavletic, MR Bishop, SR Tarantolo, S Martin-Algarra, PJ Bierman, JM Vose, EC Reed, TG Gross, J Kollath, K Nasrati, JD Jackson, JO Armitage and A Kessinger
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330, USA.

PURPOSE: To compare hematopoietic recovery, duration of hospitalization, and 100-day survival in patients who received allogeneic-blood stem cells (BSC) or conventional allogeneic bone marrow transplantation (BMT). PATIENTS AND METHODS: From December 1994 to August 1995, 21 patients participated in a phase II study of allogeneic BSC transplantation. Cells mobilized with granulocyte colony- stimulating factor (G-CSF; 5 micrograms/kg/ d) were collected from human leukocyte antigen (HLA)-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. G-CSF (10 micrograms/kg/d) was administered posttransplant. The outcomes were compared with 22 identically treated historical patients who received allogeneic BMT. RESULTS: The median infused CD34+ cell and granulocyte-macrophage colony-forming unit (CFU- GM) content were 7.73 x 10(4)/kg and 41.6 x 10(4)/kg, respectively. The median time to a neutrophil count greater than 500/ microL was 11 days after BSC and 16.5 days after BMT (P = .0003). A trend toward faster platelet and RBC recovery after BSC was observed. BSC patients received fewer platelet transfusions: 10 versus 19 (P = .015). The median length of hospitalization was shorter after BSC transplantation: 25 versus 31.5 days (P = .0243). The 100-day survival rates were similar: 83% after BSC and 75% after BMT (P = .3585). The incidence of acute GVHD grade II to IV was 57% and 45% for BSC and BMT, respectively (P = .4654). CONCLUSION: In comparison to BMT, allogeneic BSC transplantation may result in faster hematopoietic recovery, shorter hospital stay, and similar early survival. Whether allogeneic BSC are superior to bone marrow needs to be determined in randomized trials.

This article has been cited by other articles:

				C. Talarn, A. Urbano-Ispizua, R. Martino, J. A. Perez-Simon, M. Batlle, C. Herrera, M. Granell, A. Gaya, M. Torrebadell, F. Fernandez-Aviles, et al. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome Haematologica, December 1, 2007; 92(12): 1655 - 1663. [Abstract] [Full Text] [PDF]

				A. R. Fraser, G. Cook, I. M. Franklin, J. G. Templeton, M. Campbell, T. L. Holyoake, and J. D. M. Campbell Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity J. Leukoc. Biol., October 1, 2006; 80(4): 862 - 869. [Abstract] [Full Text] [PDF]

				A. Dominietto, T. Lamparelli, A. M. Raiola, M. T. Van Lint, F. Gualandi, G. Berisso, S. Bregante, C. di Grazia, M. Soracco, A. Pitto, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation Blood, December 1, 2002; 100(12): 3930 - 3934. [Abstract] [Full Text] [PDF]

				S. Couban, D. R. Simpson, M. J. Barnett, C. Bredeson, L. Hubesch, K. Howson-Jan, T. B. Shore, I. R. Walker, P. Browett, H. A. Messner, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies Blood, August 13, 2002; 100(5): 1525 - 1531. [Abstract] [Full Text] [PDF]

				M. E. D. Flowers, P. M. Parker, L. J. Johnston, A. V. B. Matos, B. Storer, W. I. Bensinger, R. Storb, F. R. Appelbaum, S. J. Forman, K. G. Blume, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial Blood, June 28, 2002; 100(2): 415 - 419. [Abstract] [Full Text] [PDF]

				P. Guardiola, V. Runde, A. Bacigalupo, T. Ruutu, F. Locatelli, M. A. Boogaerts, A. Pagliuca, J. J. Cornelissen, H. C. Schouten, E. Carreras, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes Blood, May 29, 2002; 99(12): 4370 - 4378. [Abstract] [Full Text] [PDF]

				H. Bittencourt, V. Rocha, S. Chevret, G. Socie, H. Esperou, A. Devergie, L. Dal Cortivo, J.-P. Marolleau, F. Garnier, P. Ribaud, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation Blood, April 15, 2002; 99(8): 2726 - 2733. [Abstract] [Full Text] [PDF]

				J. M. Prieto, J. Blanch, J. Atala, E. Carreras, M. Rovira, E. Cirera, and C. Gasto Psychiatric Morbidity and Impact on Hospital Length of Stay Among Hematologic Cancer Patients Receiving Stem-Cell Transplantation J. Clin. Oncol., April 1, 2002; 20(7): 1907 - 1917. [Abstract] [Full Text] [PDF]

				J. Morton, C. Hutchins, and S. Durrant Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells Blood, December 1, 2001; 98(12): 3186 - 3191. [Abstract] [Full Text] [PDF]

				S. S. Joshi, J. C. Lynch, S. Z. Pavletic, S. R. Tarantolo, S. J. Pirruccello, A. Kessinger, and M. R. Bishop Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics Blood, September 15, 2001; 98(6): 1963 - 1970. [Abstract] [Full Text] [PDF]

				C. Cutler, S. Giri, S. Jeyapalan, D. Paniagua, A. Viswanathan, and J. H. Antin Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis J. Clin. Oncol., August 15, 2001; 19(16): 3685 - 3691. [Abstract] [Full Text] [PDF]

				D. Przepiorka, T. L. Smith, J. Folloder, P. Anderlini, K.-W. Chan, M. Korbling, B. Lichtiger, F. Norfleet, and R. Champlin Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors Blood, June 1, 2001; 97(11): 3405 - 3410. [Abstract] [Full Text] [PDF]

				C. Cutler and J. H. Antin Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review Stem Cells, February 1, 2001; 19(2): 108 - 117. [Abstract] [Full Text]

				H. Matsubara, A. Makimoto, J. Takayama, T. Higa, T. Saito, Y. Kanda, R. Tanosaki, S. Mineishi, M. Ohira, and Y. Takaue Possible Clinical Benefits of the Use of Peripheral Blood Stem Cells Over Bone Marrow in the Allogeneic Transplantation Setting for the Treatment of Childhood Leukemia Jpn. J. Clin. Oncol., January 1, 2001; 31(1): 30 - 34. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				M. S. Tallman, P. A. Rowlings, G. Milone, M.-J. Zhang, W. S. Perez, D. Weisdorf, A. Keating, R. P. Gale, R. B. Geller, M. J. Laughlin, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission Blood, August 15, 2000; 96(4): 1254 - 1258. [Abstract] [Full Text] [PDF]

				M. R. Bishop, S. R. Tarantolo, R. B. Geller, J. C. Lynch, P. J. Bierman, Z. S. Pavletic, J. M. Vose, S. Kruse, S. P. Dix, M. E. Morris, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation Blood, July 1, 2000; 96(1): 80 - 85. [Abstract] [Full Text] [PDF]

				R. E. Champlin, N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza Jr, B. Hertenstein, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation Blood, June 15, 2000; 95(12): 3702 - 3709. [Abstract] [Full Text] [PDF]

				D. Przepiorka, T. L. Smith, J. Folloder, I. Khouri, N. T. Ueno, R. Mehra, M. Korbling, Y. O. Huh, S. Giralt, J. Gajewski, et al. Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation Blood, August 15, 1999; 94(4): 1465 - 1470. [Abstract] [Full Text] [PDF]

				M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection J. Clin. Oncol., July 1, 1999; 17(7): 2160 - 2160. [Abstract] [Full Text] [PDF]

				R. A. Brown, D. Adkins, H. Khoury, R. Vij, L. T. Goodnough, S. Shenoy, and J. F. DiPersio Long-Term Follow-Up of High-Risk Allogeneic Peripheral-Blood Stem-Cell Transplant Recipients: Graft-Versus-Host Disease and Transplant-Related Mortality J. Clin. Oncol., March 1, 1999; 17(3): 806 - 806. [Abstract] [Full Text] [PDF]

				M. Neipp, T. Zorina, M. A. Domenick, B. G. Exner, and S. T. Ildstad Effect of FLT3 Ligand and Granulocyte Colony-Stimulating Factor on Expansion and Mobilization of Facilitating Cells and Hematopoietic Stem Cells in Mice: Kinetics and Repopulating Potential Blood, November 1, 1998; 92(9): 3177 - 3188. [Abstract] [Full Text] [PDF]

				M. Mielcarek, L. Graf, G. Johnson, and B. Torok-Storb Production of Interleukin-10 by Granulocyte Colony-Stimulating Factor-Mobilized Blood Products: A Mechanism for Monocyte-Mediated Suppression of T-Cell Proliferation Blood, July 1, 1998; 92(1): 215 - 222. [Abstract] [Full Text] [PDF]